

# Correspondence



# Hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer



Department of Gynecologic Cancer, Shaanxi Provincial Tumor Hospital, Xian, China

Tao Wu D, Xi-Xia Zhao D, Guo-Qing Wang

Received: Feb 20, 2018 Accepted: Mar 3, 2018

#### Correspondence to

#### **Guo-Qing Wang**

Department of Gynecologic Cancer, Shaanxi Provincial Tumor Hospital, No. 302 Yanta West Road, Xian, Shaanxi 710061, China. E-mail: wgq5668@163.com

Copyright © 2018. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

### **ORCID** iDs

Tao Wu 🗓

https://orcid.org/0000-0003-2725-8442 Xi-Xia Zhao

https://orcid.org/0000-0002-7851-1906 Guo-Qing Wang (D

https://orcid.org/0000-0001-9665-5279

## **Conflict of Interest**

No potential conflict of interest relevant to this article was reported.

#### **Author Contributions**

Conceptualization: W.T., Z.X.X., W.G.Q.; Formal analysis: W.T., Z.X.X., W.G.Q.; Investigation: W.T.; Supervision: Z.X.X., W.G.Q.; Validation: Z.X.X., W.G.Q.; Writing - original draft: W.T.; Writing - review & editing: Z.X.X., W.G.Q.

To the editor,

We read with great interest the recently published article by van Driel et al. [1] in *The New England Journal of Medicine*, which reported that the single administration of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) increases survival in patients with advanced ovarian cancer. This finding is encouraging; however, some aspects of the study warrant closer attention.

First, lymph node involvement is common in advanced ovarian cancer that is an established prognostic factor. The extent of lymphadenectomy and the number of positive nodes are associated with survival of patients with advanced ovarian cancer [2]. The current recommendations regarding lymphadenectomy in advanced ovarian cancer remain debatable. Did all the trial patients receive systematic lymphadenectomy or lymph node sampling as a part of CRS? This trial did not report surgery information about lymphadenectomy, which was a potential confounding factor. Second, intraabdominal temperature of 40.0°C was maintained in this trial, but in another randomized phase III study by Spiliotis et al. [3], the temperature setting of HIPEC was 42.5°C. Therefore, it would be interesting to know whether the increase of temperature in HIPEC within an appropriate range will improve the outcome. In addition, a study [4] has suggested that HIPEC with cisplatin and paclitaxel after CRS is feasible with acceptable morbidity, the role of which merits further investigations.

In short, despite the scientific merit of this trial, further clinical studies are necessary before HIPEC can become a practice-changing option for advanced ovarian cancer.

## **REFERENCES**

- van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HW, Hermans RH, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018;378:230-40.
  PUBMED | CROSSREF
- Chan JK, Urban R, Hu JM, Shin JY, Husain A, Teng NN, et al. The potential therapeutic role of lymph node resection in epithelial ovarian cancer: a study of 13918 patients. Br J Cancer 2007;96:1817-22.
  PUBMED | CROSSREF

https://ejgo.org



3. Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 2015;22:1570-5.

PUBMED | CROSSREF

 Coccolini F, Campanati L, Catena F, Ceni V, Ceresoli M, Jimenez Cruz J, et al. Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. J Gynecol Oncol 2015;26:54-61.
PUBMED | CROSSREF